Početna stranicaTTNP • NASDAQ
add
Titan Pharmaceuticals, Inc. common stock
3,73 $
Poslije radnog vremena:(3,49 %)+0,13
3,86 $
Zatvoreno: 30. tra, 19:02:14 GMT -4 · USD · NASDAQ · Odricanje od odgovornosti
Preth. zaklj. cijena
3,75 $
Dnevni raspon
3,67 $ - 3,73 $
Godišnji raspon
3,03 $ - 14,80 $
Tržišna kapitalizacija
3,41 mil. USD
Prosječna količina
22,80 tis.
P/E omjer
-
Prinos dividende
-
Glavno tržište vrijednosnica
NASDAQ
Vijesti s tržišta
Financijski podaci
Račun dobiti i gubitka
Prihod
Neto dohodak
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Prihod | — | — |
Operativni troškovi | 666,00 tis. | −53,88 % |
Neto dohodak | −790,00 tis. | 59,90 % |
Neto profitabilnost | — | — |
Zarada po dionici | — | — |
EBITDA | −666,00 tis. | 65,46 % |
Efektivna porezna stopa | — | — |
Bilanca stanja
Ukupna imovina
Ukupne obveze
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Gotovinska i kratkoročna ulaganja | 2,83 mil. | −58,12 % |
Ukupna imovina | 2,92 mil. | −63,85 % |
Ukupne obveze | 483,00 tis. | −66,55 % |
Ukupni kapital | 2,44 mil. | — |
Dionice u optjecaju | 914,23 tis. | — |
Cijena prema knjigovodstvenoj vrijednosti | 1,40 | — |
Povrat imovine | −51,03 % | — |
Povrat kapitala | −58,72 % | — |
Tok novca
Neto promjena novca
| (USD) | pro 2024.info | Godišnja promjena |
|---|---|---|
Neto dohodak | −790,00 tis. | 59,90 % |
Gotovina od poslovanja | −506,00 tis. | 77,47 % |
Gotovina iz ulaganja | — | — |
Gotovina iz financiranja | −62,00 tis. | −115,27 % |
Neto promjena novca | −568,00 tis. | 57,49 % |
Slobodan tok novca | −193,25 tis. | 80,89 % |
Više
Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA, developing proprietary therapeutics primarily for treating central nervous system disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds. In the same month, it also posted approximately $1.7 million in revenue, in large part drawn from its licensing for its European intellectual property rights for Probuphine to the Italian pharmaceutical company Molteni – a leading European opioid manufacturer and also a subsidiary of the German Pharmaceutical juggernaut Merck Group.
Titan's principal asset is Probuphine, a slow-release implant formulation of buprenorphine for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. Wikipedia
Osnovano
1991
Web-lokacija
Zaposlenici
4
